文献速递前列腺癌

Galeterone对比恩杂鲁胺治疗AR-V7阳性mCRPC的III期随机试验

Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer.
PubMed 文献 · Eur Urol · 2019-09-18

这项多中心III期随机试验对未接受过恩杂鲁胺、阿比特龙和化疗的mCRPC患者进行AR-V7预筛查,AR-V7阳性者随机接受galeterone或恩杂鲁胺。因rPFS事件删失率高,数据监测委员会建议提前终止试验,未达到主要终点,galeterone不再继续开发。

要点

  • 一线mCRPC中CTC mRNA AR-V7阳性率为8%(95%CI 6-10%)。
  • AR-V7阳性与更高PSA、更多骨转移等侵袭性疾病特征相关。
  • 因rPFS事件删失率高,试验提前终止,galeterone不继续开发。

核心结论

  • 在AR-V7阳性mCRPC中,因rPFS事件删失率高,数据监测委员会基于中期证据建议提前终止试验,主要终点未达到,galeterone不再继续开发。

研究设计与样本

  • 多中心随机III期试验,对未接受过恩杂鲁胺、阿比特龙和化疗的mCRPC患者用基于CTC的mRNA检测预筛查AR-V7。
  • AR-V7阳性患者按1:1随机接受开放标签galeterone或恩杂鲁胺,计划样本量148例。
  • 共953例男性预筛查AR-V7,323例(34%)可检测到CTC,73/323例有AR-V7 mRNA。

主要发现

  • AR-V7阳性率为8%(73/953;95%CI 6-10%)。
  • AR-V7与基线更高PSA水平(p<0.001)、更多骨转移(p<0.001)、激素敏感期使用多西他赛(p<0.001)、既往第一代雄激素剥夺治疗(p<0.001)及更短诊断至入组时间(p<0.001)相关。
  • 73例合格患者中38例随机分配至galeterone(n=19)或恩杂鲁胺(n=19),35例在随机前退出。
  • PSA50在galeterone组为2/16(13%),恩杂鲁胺组为8/19(42%),比例差-0.278(95%CI -0.490至0.097)。

临床怎么用

  • 一线mCRPC患者中CTC mRNA AR-V7阳性率为8%,且与侵袭性、晚期疾病特征相关,提示疾病进展迅速。

局限性

  • 因rPFS事件删失率高,试验提前终止,未能确定疗效。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Detection of androgen receptor (AR) splice variant-7 (AR-V7) messenger RNA (mRNA) in circulating tumor cells (CTCs) is associated with a suboptimal response to abiraterone and enzalutamide in metastatic castration-resistant prostate cancer (mCRPC). Galeterone inhibits CYP17 and AR, and induces AR protein degradation. We hypothesized that galeterone would be clinically superior to enzalutamide in AR-V7-positive (AR-V7+) mCRPC. OBJECTIVE: To screen and characterize AR-V7+ mCRPC, and evaluate galeterone compared with enzalutamide. DESIGN, SETTING, AND PARTICIPANTS: This was a multicenter randomized phase 3 trial; enzalutamide-, abiraterone-, and chemotherapy-naïve mCRPC patients had AR-V7 prescreening using a CTC-based mRNA assay. INTERVENTION: AR-V7+ patients were randomized (1:1) to open-label galeterone or enzalutamide; planned sample size was 148. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The primary endpoint was radiographic progression-free survival (rPFS). Baseline AR-V7 status was correlated with patient characteristics. RESULTS AND LIMITATIONS: Overall, 953 men were prescreened for AR-V7; 323 (34%) had detectable CTCs, and 73/323 had AR-V7 mRNA. The AR-V7+ prevalence was 8% (73/953; 95% confidence interval [CI] 6-10%). AR-V7 was associated with indicators of advanced and high-volume disease at baseline, including higher prostate-specific antigen (PSA) level (p < 0.001), more bone metastases (p < 0.001), docetaxel for hormone-sensitive disease (p < 0.001), prior first-generation androgen deprivation therapy (p < 0.001), and shorter time from diagnosis to enrollment (p < 0.001). Of 73 eligible patients, 38 were randomized to galeterone (n=19) or enzalutamide (n=19); 35 dropped out before randomization. Owing to high censorship for the rPFS events, the data monitoring committee recommended early closure based on interim evidence that the primary endpoint would not be met. The PSA50 values were 2/16 (13%) and 8/19 (42%) for galeterone and enzalutamide respectively (proportion difference=-0.278, 95% CI -0.490 to 0.097). CONCLUSIONS: The prevalence of CTC mRNA AR-V7 in first-line mCRPC was 8% (95% CI 6-10%). AR-V7+ was associated with the characteristics of aggressive and advanced disease. These men had rapid disease progression. Development of galeterone will not be pursued. PATIENT SUMMARY: Of men with metastatic castration-resistant prostate cancer, 8% had the androgen receptor splice variant-7 (AR-V7) blood biomarker. The AR-V7+ patients had features of aggressive disease. Thirty-eight men were treated with either galeterone or enzalutamide; the trial was stopped early prior to determining efficacy because too many patients transitioned off the trial due to advancing cancer before having required radiographs.

来源:Eur Urol,查看原文。版权归原作者所有。

引用

  1. Taplin ME, Antonarakis ES, Ferrante KJ, et al. Androgen Receptor Modulation Optimized for Response-Splice Variant: A Phase 3, Randomized Trial of Galeterone Versus Enzalutamide in Androgen Receptor Splice Variant-7-expressing Metastatic Castration-resistant Prostate Cancer. Eur Urol. 2019. PMID: 31542304. doi:10.1016/j.eururo.2019.08.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。